Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ganeden warning letter revisited

This article was originally published in The Tan Sheet

Executive Summary

FDA reposted a warning letter on its Web site for Ganeden Biotech. FDA removed the 1letter in March while it was in discussions with Ganeden (2"The Tan Sheet" March 5, 2007, In Brief). An FDA spokesperson says no changes were made to the letter. The letter states some of the firm's Digestive Advantage products are misbranded foods and unapproved news drugs. The products were labeled as medical foods, which FDA says is incorrect...

You may also be interested in...



Ganeden Biotech warning letter

The FDA warning letter sent to medical foods marketer Ganeden Biotech and reported in the Feb. 26 issue of "The Tan Sheet" has been removed from the agency's Web site. An FDA spokesperson told "The Tan Sheet" the letter was issued by the agency's Cincinnati office, but FDA is now in discussions with the firm over whether to withdraw the letter. The spokesperson noted that, as far as FDA is concerned, a letter was issued, and the decision to withdraw the letter was FDA's (1"The Tan Sheet" Feb. 26, 2007, In Brief)...

J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints

If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.

Woodcock To Be Acting US FDA Commissioner; Sharfstein Tops Biden's List Of Candidates For Post

Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel